FDA Accepts Xspray Pharma ’s NDA-Resubmission for Dasynoc

Stockholm, Sweden– 2024-02-12 Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma’s New Drug Application (NDA) for Dasynoc®, following a...

https://www.drugs.com/nda/dasynoc_240212.html

Source: Drugs.com - New Drug Applications - February 12, 2024 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications | Pharmaceuticals | Sweden Health